Skip to content

Effect of a Novel Melatonin Supplement on Sleep Quality

Effect of a Novel Melatonin Supplement on Sleep Quality

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06215573
Acronym
I-MASQ
Enrollment
15
Registered
2024-01-22
Start date
2023-12-04
Completion date
2024-04-18
Last updated
2025-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sleep

Keywords

melatonin, pharmacokinetics, sleep quality

Brief summary

Melatonin is a hormone naturally found in our body that increases in our blood at night and controls how we sleep. Melatonin can also be taken as a pill and numerous clinical trials have documented improved sleep quality following melatonin supplementation before bed. However, it is not known whether such supplements actually increase blood melatonin above normal levels, particularly at night. The aims of this study are to investigate whether a novel melatonin supplement (Ritual Sleep BioSeriesTM Melatonin) can increase blood melatonin in human participants at night, and to determine if taking the supplement before bed for two-weeks can improve sleep quality.

Interventions

DIETARY_SUPPLEMENTMelatonin

5mg melatonin supplement, once daily, from Ritual BioSeries

DIETARY_SUPPLEMENTPlacebo supplement

Placebo supplement, once daily, from Ritual BioSeries

Sponsors

Ritual Inc.
CollaboratorUNKNOWN
University of Exeter
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

Coded, known only to manufacturer / collaborator

Intervention model description

Randomised cross over trial counterbalanced for trial order

Eligibility

Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy * Aged 18-40 * Sometimes have trouble sleeping (Pittsburgh sleep quality index score \>5)

Exclusion criteria

* Routinely taking melatonin supplements or other drugs known to affect sleep * A diagnosed sleep disorder * Major psychiatric illness * Current physical injury * Known or suspected hypersensitivity to melatonin * Presence of major sleep disruptors at home (e.g. new born baby) * Night shift/rotational-shift work * Receiving non-pharmacological treatment for sleep disorder (e.g. cognitive behavioral therapy) * Substance use disorder * Recent (\<1 month) increase in daily caffeinated drink consumption * Consuming \>14 standard alcoholic drinks per week * Pregnant or lactating

Design outcomes

Primary

MeasureTime frameDescription
Pharmacokinetic10 hoursSerum melatonin concentration area under curve
Sleep efficiency2 weeksSleep efficiency, as total time asleep as percentage of time in bed

Secondary

MeasureTime frameDescription
Sleep diary2 weeksSleep diary recorded daily via 'consensus sleep diary - core'
Recovery and well being2 weeksRecovery and well being recorded via recovery stress questionnaire (REST-Q)
Sleep quality2 weeksSleep quality determined via 'Pittsburgh Sleep Quality Index survey'

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026